Announcements Trials
Browse Landscape

Phase

Phase 3 29Phase 2 16Phase 1/2 4Phase 4 3Phase 1 3Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 4

Conditions

Urinary Bladder Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 2

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Mitomycin × Genitourinary × Clear all
NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

University of Washington

Phase 1/2 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Mayo Clinic

Phase 1/2 Recruiting
40 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03844256 2022-08-12

CRIMI

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Recruiting
50 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00318643 2021-10-29

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Halozyme Therapeutics

Phase 1/2 Completed
27 enrolled 14 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡